Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE W CODEINE versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE W CODEINE versus TAVIST 1.
PROMETHAZINE W/ CODEINE vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits nociceptive transmission; promethazine is a phenothiazine derivative with H1-receptor antagonism, anticholinergic, and antiemetic effects.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
10 mL (1 mg codeine, 6.25 mg promethazine per 5 mL) orally every 4-6 hours as needed for cough. Maximum: 60 mL per day. Do not exceed 5 days.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Promethazine: 10-19 hours (terminal). Codeine: 2.5-3.5 hours (terminal); prolonged in renal impairment.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Promethazine: renal (70% as metabolites, <1% unchanged), fecal (20-30%). Codeine: renal (90%, of which 5-10% unchanged, rest as metabolites), fecal (minor).
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine